TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34800988

Group type: EXPERIMENTAL
Intervention: Postoperative physical therapy
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Regular physical activity
Number of subjects: 157

Group type: COMPARATOR
Intervention: Pain levels during hospitalization
Number of subjects: 157

Group type: COMPARATOR
Intervention: Size of tumors
Number of subjects: 157

Group type: COMPARATOR
Intervention: Breast reconstructions
Number of subjects: 157

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 157

Group type: COMPARATOR
Intervention: More than three dissected lymph nodes
Number of subjects: 157

Group type: COMPARATOR
Intervention: Presence of preoperative pain
Number of subjects: 157

Group type: COMPARATOR
Intervention: In-hospital pain
Number of subjects: 157

Group type: COMPARATOR
Intervention: Axillary web syndrome
Number of subjects: 157

Group type: COMPARATOR
Intervention: Lymphedema
Number of subjects: 157

Group type: COMPARATOR
Intervention: Radiation
Number of subjects: 157

Group type: COMPARATOR
Intervention: Size of dissected tissue
Number of subjects: 157
Study: 34801015

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Number of subjects: 737

Group type: COMPARATOR
Intervention: Conventional therapy (calcium and active vitamin D)
Number of subjects: 737
Study: 34801051

Group type: EXPERIMENTAL
Intervention: Weifuchun (WFC) tablets, 1.44 g three times a day for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitacoenzyme (Vit) tablets, 0.8 g three times a day for 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WFC treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parabacteroides
Number of subjects: 0
Study: 34801354

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W plus trametinib 1.5 mg QD (concurrent DL2a)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W plus trametinib 2 mg QD (intermittent DL2)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W plus trametinib 1.5 mg QD (concurrent DL1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W plus trametinib 1.5 mg QD (concurrent DL2b)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W plus trametinib 2 mg QD (intermittent DL1)
Number of subjects: 42
Study: 34801462

Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Number of subjects: 71
Study: 34801581

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (SGLT2i)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control (non-diabetic recipients)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Diabetic recipients without SGLT2i
Number of subjects: 77
Study: 34801592

Group type: EXPERIMENTAL
Intervention: Sputum biomarkers (sialic acid, hypoxanthine, xanthine, methylthioadenosine, adenine, glutathione)
Number of subjects: 980
Study: 34801735

Group type: EXPERIMENTAL
Intervention: ECG patch monitoring pre-, immediately post-, and 2-3 months post-TAVR
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: ECG patch monitoring
Number of subjects: 96
Study: 34801749

Group type: EXPERIMENTAL
Intervention: Aumolertinib (110 mg orally once daily)
Number of subjects: 244
Study: 34802036

Group type: EXPERIMENTAL
Intervention: Hypothermia treatment
Number of subjects: 479
Study: 34802344

Group type: EXPERIMENTAL
Intervention: Health-related present bias (PB)
Number of subjects: 0
Study: 34802428

Group type: EXPERIMENTAL
Intervention: Simulation exercises as a teaching method
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Creating a safe environment, facilitating student-centred learning, and promoting reflection
Number of subjects: 6
Study: 34802427

Group type: EXPERIMENTAL
Intervention: Flexible and integrated treatment (FIT) model project at the model hospital
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes in the model hospital
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 600
Study: 34802455

Group type: EXPERIMENTAL
Intervention: Permethrin-treated uniform with 30% DEET liposome formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Permethrin-treated uniform with placebo lotion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etofenprox-treated uniform with 30% DEET liposome formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated uniforms with placebo lotion
Number of subjects: 0
Study: 34802467

Group type: EXPERIMENTAL
Intervention: Bilberry/red grape juice
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 60
Study: 34802696

Group type: EXPERIMENTAL
Intervention: Sevoflurane general anaesthesia
Number of subjects: 72
Study: 34802792

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine (first dose)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine (second dose)
Number of subjects: 96
Study: 34802864

Group type: EXPERIMENTAL
Intervention: Nivolumab 360 mg and docetaxel 75 mg/m²
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Nivolumab plus docetaxel
Number of subjects: 84
Study: 34802966

Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg initiated, average dose 45.5 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cabozantinib (treatment line subgroups)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cabozantinib (CCI score comparison)
Number of subjects: 100
Study: 34803050

Group type: EXPERIMENTAL
Intervention: Collaborative Care Intervention plus Cancer Prevention Care Management (CCI+PCM)
Number of subjects: 757

Group type: COMPARATOR
Intervention: Cancer Prevention Care Management (PCM) alone
Number of subjects: 757
Study: 34803301

Group type: EXPERIMENTAL
Intervention: Nanohydroxyapatite (NHA)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Formocresol (FC)
Number of subjects: 72
Study: 34803760

Group type: EXPERIMENTAL
Intervention: Cannabidiol Cigarettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34803777

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 124
Study: 34803851

Group type: EXPERIMENTAL
Intervention: Enhancing left beta/theta power ratio NF training in combination with reducing right beta/theta power ratio NF training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham NF training
Number of subjects: 0
Study: 34803867

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0
Study: 34804205

Group type: EXPERIMENTAL
Intervention: Field Assessment Stroke Triage for Emergency Destination ⩾4
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Smartphone app-based stroke triage
Number of subjects: 200
Study: 34804358

Group type: EXPERIMENTAL
Intervention: Acne lesion extraction every two weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Oral doxycycline 100mg once daily
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: HIF-1 alpha expression
Number of subjects: 140
Study: 34804608

Group type: EXPERIMENTAL
Intervention: Metformin-inclusive sulfonylurea
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sulphonylurea(s) monotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (30 controls)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nondiabetic parkinsonian patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (10 controls)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All parkinsonian patients
Number of subjects: 60
Study: 34804848

Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg weekly
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Physician's prognosis
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: MSKCC score
Number of subjects: 547
Study: 34804993

Group type: EXPERIMENTAL
Intervention: Overexpression of virulent bacteria in the gut microbiota of the patient with advanced colorectal tumor.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Healthy twin sister's gut microbiota composition.
Number of subjects: 2
Study: 34805034

Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching with Parents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34805058

Group type: EXPERIMENTAL
Intervention: Adherence to the Mediterranean diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-adherence to the Mediterranean diet
Number of subjects: 0
Study: 34805212

Group type: EXPERIMENTAL
Intervention: Position change from the bed to a wheelchair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34805240

Group type: EXPERIMENTAL
Intervention: Plasma Vitamin E levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34805629

Group type: EXPERIMENTAL
Intervention: CathPR (catheter port reversal)
Number of subjects: 23
Study: 34805632

Group type: EXPERIMENTAL
Intervention: AZD5718 (5-Lipoxygenase Activating Protein Inhibitor)
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: AZD5718 plus dapagliflozin (10 mg/d)
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: AZD5718
Number of subjects: 632

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 632
Study: 34805723

Group type: EXPERIMENTAL
Intervention: Whole-grain diet (50 g/1000 kcal per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Refined-grain diet (macronutrient-matched)
Number of subjects: 0
Study: 34806137

Group type: EXPERIMENTAL
Intervention: Dupilumab plus topical corticosteroids (TCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dupilumab plus TCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus TCS
Number of subjects: 0
Study: 34806155

Group type: EXPERIMENTAL
Intervention: GB242
Number of subjects: 570

Group type: COMPARATOR
Intervention: Infliximab (INF)
Number of subjects: 570
Study: 34806163

Group type: EXPERIMENTAL
Intervention: GELAD chemotherapy regimen (gemcitabine 1.0 g/m²)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sandwiched radiotherapy
Number of subjects: 0
Study: 34806762

Group type: COMPARATOR
Intervention: Renal denervation
Number of subjects: 1416
Study: 34806912

Group type: EXPERIMENTAL
Intervention: Continuous intraoperative CSF pressure monitoring during surgical decompression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical decompression
Number of subjects: 0
Study: 34806998

Group type: EXPERIMENTAL
Intervention: Health education through a CKD campaign facilitated by a nephrologist and mHealth (periodic mobile phone calls) from community health workers
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 126
Study: 34806997

Group type: EXPERIMENTAL
Intervention: AFib 2gether mobile app
Number of subjects: 37
Study: 34807306

Group type: EXPERIMENTAL
Intervention: 3D biplane ultrasound imaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional 2D ultrasound imaging
Number of subjects: 0
Study: 34807657

Group type: EXPERIMENTAL
Intervention: Active ABMT
Number of subjects: 145

Group type: COMPARATOR
Intervention: Sham ABMT
Number of subjects: 145

Group type: COMPARATOR
Intervention: Assessments only
Number of subjects: 145
Study: 34807722

Group type: EXPERIMENTAL
Intervention: Management without anticoagulation
Number of subjects: 266
Study: 34807883

Group type: EXPERIMENTAL
Intervention: Fesoterodine
Number of subjects: 75
Study: 34807979

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control (no rivaroxaban)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Baseline biomarkers
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Survivors vs. those who died
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Regression analyses
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Pathway analysis
Number of subjects: 124
Study: 34807989

Group type: EXPERIMENTAL
Intervention: Macrolides
Number of subjects: 1973
Study: 34808103

Group type: EXPERIMENTAL
Intervention: Higher levels of glycemic markers
Number of subjects: 2290
Study: 34808524

Group type: EXPERIMENTAL
Intervention: Combinations of six molecularly targeted agents and a PD-L1 antagonist
Number of subjects: 140
Study: 34808624

Group type: EXPERIMENTAL
Intervention: rhythmic speech-language therapy (rSLT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: rhythmic balance-mobility training (rBMT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: no-therapy (NT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: healthy controls (HC)
Number of subjects: 44
Study: 34808697

Group type: EXPERIMENTAL
Intervention: Adjuvant growth hormone (GH) in IVF
Number of subjects: 1352

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 1352
Study: 34809482

Group type: EXPERIMENTAL
Intervention: Specialized Technology Education for Pumps and Pens
Number of subjects: 0
Study: 34809507

Group type: EXPERIMENTAL
Intervention: Apixaban discontinuation prior to surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34809579

Group type: EXPERIMENTAL
Intervention: Preoperative sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI) questionnaire
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Age of patients
Number of subjects: 59

Group type: COMPARATOR
Intervention: Emergence delirium (ED) group
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Watcha scale score
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: PAED scale score
Number of subjects: 59
Study: 34809974

Group type: EXPERIMENTAL
Intervention: Total folate intake up to 1,200 μg/d
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Supplemental folate intake up to 800 μg/d
Number of subjects: 552
Study: 34810040

Group type: EXPERIMENTAL
Intervention: Perceived neighborhood-built environment attributes (walking/cycling facilities)
Number of subjects: 2478

Group type: EXPERIMENTAL
Intervention: Perceived neighborhood-built environment attributes (land use mix-diversity)
Number of subjects: 2478

Group type: EXPERIMENTAL
Intervention: Perceived neighborhood-built environment attributes (aesthetics)
Number of subjects: 2478

Group type: EXPERIMENTAL
Intervention: Perceived neighborhood-built environment attributes (safety from traffic)
Number of subjects: 2478
Study: 34810067

Group type: EXPERIMENTAL
Intervention: NPC1 patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 30
Study: 34810184

Group type: EXPERIMENTAL
Intervention: Childhood ALL survivors
Number of subjects: 675

Group type: COMPARATOR
Intervention: Matched references
Number of subjects: 675
Study: 34810187

Group type: EXPERIMENTAL
Intervention: VRi vestibular rehabilitation intervention based on the conventional Cawthorne-Cooksey protocol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional Cawthorne-Cooksey protocol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: VRi vestibular rehabilitation intervention
Number of subjects: 30
Study: 34810193

Group type: EXPERIMENTAL
Intervention: 8-week interactive informational mobile health intervention on COVID-19 prevention practices
Number of subjects: 385
Study: 34810276

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 274
Study: 34811954

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 425

Group type: COMPARATOR
Intervention: Valsartan (control)
Number of subjects: 425
Study: 34812195

Group type: EXPERIMENTAL
Intervention: Passive recharge burst spinal cord stimulation (B-SCS)
Number of subjects: 0
Study: 34812424

Group type: EXPERIMENTAL
Intervention: Sarilumab (400 mg intravenously on day 1 and on day 3 if clinically indicated)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 148
Study: 34812733

Group type: EXPERIMENTAL
Intervention: Discussion group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Wiki
Number of subjects: 20

Group type: COMPARATOR
Intervention: Focus groups
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wikis
Number of subjects: 20
Study: 34812928

Group type: EXPERIMENTAL
Intervention: Paced Auditory Serial Addition Task (PASAT) training
Number of subjects: 46
Study: 34813044

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 480
Study: 34813048

Group type: EXPERIMENTAL
Intervention: PMT-informed intervention
Number of subjects: 995
Study: 34813082

Group type: EXPERIMENTAL
Intervention: Active information provision
Number of subjects: 8389

Group type: EXPERIMENTAL
Intervention: Passive information provision
Number of subjects: 8389
Study: 34813191

Group type: EXPERIMENTAL
Intervention: POCUS algorithm for diagnosing AHF
Number of subjects: 103
Study: 34813486

Group type: EXPERIMENTAL
Intervention: VR treatment (self-guided, mobile app-based VR CBT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 54
Study: 34813485

Group type: EXPERIMENTAL
Intervention: 360° VR video
Number of subjects: 32

Group type: COMPARATOR
Intervention: 2D video
Number of subjects: 32
Study: 34813491

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Home care workers' involvement in iCBT
Number of subjects: 21
Study: 34813506

Group type: EXPERIMENTAL
Intervention: TIL infusion products
Number of subjects: 26
Study: 34813516

Group type: EXPERIMENTAL
Intervention: Neuropathic pain (pain events, duration, severity)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Opioids
Number of subjects: 345

Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Neuropathic pain presence
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Number of pain events
Number of subjects: 345
Study: 34813579

Group type: EXPERIMENTAL
Intervention: Visby STI Panel
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard-of-care clinic results
Number of subjects: 55
Study: 34813910

Group type: EXPERIMENTAL
Intervention: Once-weekly exenatide (EQW) plus usual care
Number of subjects: 14752

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 14752
Study: 34814152

Group type: EXPERIMENTAL
Intervention: Baseline serum adipsin concentration
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Serum adipsin levels
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Circulating adipsin
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Prediction model of NAFLD remission
Number of subjects: 908
Study: 34814185

Group type: EXPERIMENTAL
Intervention: Oral targeted therapy
Number of subjects: 2
Study: 34814190

Group type: EXPERIMENTAL
Intervention: Gestational Age (GA) ≤35 weeks
Number of subjects: 16462

Group type: EXPERIMENTAL
Intervention: Gestational Age (GA) ≥42 weeks
Number of subjects: 16462

Group type: EXPERIMENTAL
Intervention: Boys within multiple GA intervals
Number of subjects: 16462
Study: 34814868

Group type: EXPERIMENTAL
Intervention: Evidence-based 6-week self-management supportive care program, Cancer Thriving and Surviving
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education attention control
Number of subjects: 0
Study: 34814922

Group type: EXPERIMENTAL
Intervention: Dietary biomarker-Mediterranean diet score
Number of subjects: 642
Study: 34814935

Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (0.1 to 0.2 mg/kg/h, 2.4 to 4.8 mg/kg/day) with standard therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard therapy (lopinavir/ritonavir, hydroxychloroquine, oxygen therapy, non-invasive and invasive ventilator, antibiotic therapy, renal-replacement therapy, ECMO)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate
Number of subjects: 84
Study: 34815285

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 664
Study: 34815321

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF) exposure during pregnancy
Number of subjects: 345

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 345
Study: 34815326

Group type: EXPERIMENTAL
Intervention: Lung Ultrasound (LUS) findings
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: LUS findings
Number of subjects: 215
Study: 34815632

Group type: EXPERIMENTAL
Intervention: Single patient classifier (SPC)
Number of subjects: 875
Study: 34815708

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 459

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 459
Study: 34815790

Group type: EXPERIMENTAL
Intervention: Focused ultrasound blood-brain barrier disruption
Number of subjects: 0
Study: 34816187

Group type: EXPERIMENTAL
Intervention: SMARThealth intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 34816248

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study: 34816288

Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (late-PN)
Number of subjects: 946

Group type: COMPARATOR
Intervention: Early parenteral nutrition (early-PN)
Number of subjects: 946
Study: 34816294

Group type: EXPERIMENTAL
Intervention: 1 mg/kg methylprednisolone and 5 mg/day ruxolitinib
Number of subjects: 39
Study: 34816730

Group type: EXPERIMENTAL
Intervention: Early staged PCI (<4 weeks)
Number of subjects: 1432

Group type: COMPARATOR
Intervention: Late staged PCI (≥4 weeks)
Number of subjects: 1432
Study: 34817381

Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Conjoint analysis experiment
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Vignettes of hypothetical research studies
Number of subjects: 396
Study: 34817393

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous aerobic exercise sessions (24 sessions over 2 months)
Number of subjects: 30
Study: 34817414

Group type: EXPERIMENTAL
Intervention: Dolutegravir dispersible tablets (granules/dispersible tablets)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional dolutegravir tablets (50 mg and 25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adult FDC of abacavir/dolutegravir/lamivudine and dolutegravir/lamivudine
Number of subjects: 0
Study: 34817420

Group type: EXPERIMENTAL
Intervention: Benzodiazepine premedication
Number of subjects: 9497

Group type: COMPARATOR
Intervention: No benzodiazepine premedication
Number of subjects: 9497
Study: 34817751

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20